I-Corps: Commercialization Evaluation of a Antibiotic Delivery System for Tb

结核病是一种传染病，已经感染了地球上大约三分之一的人口。目前用于治疗该病的药团是一系列一线抗生素。导致这种疾病的微生物--结核分枝杆菌--正在对这些药物产生抗药性。这些抗药性细菌菌株正在世界各地出现。制药业可以经济地大规模生产一线药物，因此必须开发新药和新的生产方法将被证明是昂贵的，并可能导致再次出现免疫状况。这项拟议的技术不是试图发现新的抗生素，而是专注于不仅将已知的抗生素更有效地输送到细菌中，而且还将药物隐藏起来，使其不被人体免疫系统识别。拟议的技术专注于与治疗结核病的抗生素相关的药物输送。在过去的四十年里，在开发新抗生素方面所做的工作很少。S团队的这一方法使用了一到三种成分来加速某些生物活动，例如细胞新陈代谢或蛋白质任务。随着细胞活动的增加，研究小组的定理是，抗生素可以不被人体的免疫系统检测到，一旦其正常的生理过程加速，就会有更有效的吸收。大多数药物，如抗生素或抗癌药物，都有一个作用机制，服务于一项独特的任务，即阻止细胞的某一部分发挥作用。该研究小组开发了一种用于治疗结核病的一线和二线抗生素的输送系统。它已被证明可以提高卷曲霉素、阿米卡星、异烟肼和利福平1-4等抗生素的疗效。

Tuberculosis is an infectious disease that has infected approximately one third of the planet's human population. The current pharmaceutical regiment used to treat the disease is a series of front line antibiotics. The microbe responsible for this malady, Mycobacterium tuberculosis, is building up a resistance to these drugs. These drug resistance strains of bacterium are emerging around the world. The pharmaceutical industry can produce the front line drugs economically on a large scale, so having to develop new drugs and new production methods would prove costly and likely result in an immunity situation again. Rather than attempting to discover new antibiotics, the proposed technology is focused on not only delivering known antibiotics to the bacterium more efficiently, but also hiding the drug from being recognized by the body's immune system.The proposed technology is focused on drug delivery associated with antibiotics for tuberculosis. Over the past forty years little work has been done in terms of developing new antibiotics. This team?s approach uses between one and three components that accelerates some biological action, such as the cells metabolism or a proteins task. As the activity of the cell increases, the team's theorem is that the antibiotic can go undetected by the body's immune system and have a more efficient uptake once its normal physiological processes are accelerated. Most drugs, such as antibiotics or cancer drugs have a mechanism of action that serve a singular mission, to stop some part of the cell from functioning. This research team has developed a delivery system for first and second line antibiotics used in the treatment of tuberculosis. It has been demonstrated to improve the efficacy of antibiotics such as capreomycin, amikacin, isoniazid and rifampici1-4.